Your browser doesn't support javascript.
loading
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Bissonnette, R; Luger, T; Thaçi, D; Toth, D; Messina, I; You, R; Guana, A; Fox, T; Papavassilis, C; Gilloteau, I; Mrowietz, U.
Afiliación
  • Bissonnette R; Innovaderm Research Inc, Montréal, QC, Canada.
  • Luger T; Department of Dermatology, University of Münster, Münster, Germany.
  • Thaçi D; Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
  • Toth D; XLR8 Medical Research, Windsor, ON, Canada.
  • Messina I; Novartis Pharmaceuticals, East Hanover, NJ, U.S.A.
  • You R; Novartis Beijing Novartis Pharma Co. Ltd, Shanghai, China.
  • Guana A; Novartis Pharmaceuticals, East Hanover, NJ, U.S.A.
  • Fox T; Novartis Pharma AG, Basel, Switzerland.
  • Papavassilis C; Novartis Pharma AG, Basel, Switzerland.
  • Gilloteau I; Novartis Pharma AG, Basel, Switzerland.
  • Mrowietz U; Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany.
Br J Dermatol ; 177(4): 1033-1042, 2017 Oct.
Article en En | MEDLINE | ID: mdl-28580579
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Fármacos Dermatológicos / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Dermatol Año: 2017 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Fármacos Dermatológicos / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Dermatol Año: 2017 Tipo del documento: Article País de afiliación: Canadá